Traders Sell Allergan PLC (AGN) on Strength (AGN)
Investors sold shares of Allergan PLC (NYSE:AGN) on strength during trading hours on Friday. $123.68 million flowed into the stock on the tick-up and $141.79 million flowed out of the stock on the tick-down, for a money net flow of $18.11 million out of the stock. Of all equities tracked, Allergan PLC had the 0th highest net out-flow for the day. Allergan PLC traded up $3.22 for the day and closed at $237.76
A number of equities analysts recently issued reports on the stock. Vetr downgraded shares of Allergan PLC from a “strong-buy” rating to a “buy” rating and set a $283.05 price target for the company. in a research note on Monday, August 8th. Mizuho raised their target price on shares of Allergan PLC from $232.00 to $246.00 and gave the company a “neutral” rating in a research note on Friday, August 5th. JPMorgan Chase & Co. set a $325.00 target price on shares of Allergan PLC and gave the company a “buy” rating in a research note on Friday, August 5th. RBC Capital Markets reaffirmed an “outperform” rating and set a $300.00 target price (down previously from $307.00) on shares of Allergan PLC in a research note on Wednesday, August 10th. Finally, Credit Suisse Group AG set a $322.00 target price on shares of Allergan PLC and gave the company a “hold” rating in a research note on Wednesday, August 3rd. Six equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $309.13.
The firm has a market cap of $93.43 billion and a price-to-earnings ratio of 22.47. The firm has a 50-day moving average of $248.09 and a 200 day moving average of $247.61.
Allergan PLC (NYSE:AGN) last posted its quarterly earnings data on Monday, August 8th. The company reported $3.35 EPS for the quarter, topping the consensus estimate of $3.34 by $0.01. The firm had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $4.10 billion. The company’s revenue was up 1.0% compared to the same quarter last year. During the same quarter last year, the firm earned $4.41 EPS. On average, equities analysts forecast that Allergan PLC will post $14.00 earnings per share for the current fiscal year.
A hedge fund recently raised its stake in Allergan PLC stock. Dimensional Fund Advisors LP raised its position in Allergan PLC (NYSE:AGN) by 6.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,596,389 shares of the company’s stock after buying an additional 103,314 shares during the period. Allergan PLC makes up about 0.3% of Dimensional Fund Advisors LP’s investment portfolio, making the stock its 28th largest position. Dimensional Fund Advisors LP owned about 0.41% of Allergan PLC worth $498,895,000 as of its most recent SEC filing.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.